Alzheimer's Diagnostic Opportunity FDA Breakthrough Designation for Optina's Alzheimer's test signals a strong regulatory and clinical validation hook. Position this to payers and large health systems as a differentiated, early dementia diagnostic that can streamline differential diagnosis and potentially reduce downstream costs.

Retinal Deep Phenotyping Leverage the retinal imaging platform to cross-sell into neurology and cardiology by highlighting correlations between retinal biomarkers and systemic diseases such as Alzheimer's and cardiac stenosis. Target large multispecialty clinics and integrated health networks focused on aging populations.

In-Community Access Recent collaboration to develop in-community patient access programs presents a channel for regional healthcare providers and accountable care organizations. Promote scalable deployment, on-site imaging, and remote AI-assisted interpretation to expand adoption in community settings.

Funding Momentum Significant funding raised and strategic investments from ADDF and venture groups indicate strong investor confidence. Use this to reassure potential customers with a perceived near-term product maturity, clinical trial activity, and roadmap transparency.

Market Positioning Smaller company with a high-potential niche in retinal imaging AI for both eye and systemic diseases. Position Optina as a partner for large healthcare buyers seeking innovative, scalable AI diagnostics that complement existing eye-care workflows and accelerate precision medicine initiatives.